BeiGene wants to ensure access to medicines for all patients and puts patients first in the fight against cancer. We foster strong collaborations that extend to the furtherest reaches of the globe. Learn more about the BeiGene story.

BeiGene, a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced approval from the China National Medical Products Administration (NMPA) for BeiGene to begin manufacturing commercial supply of its approved anti-PD-1 antibody, tislelizumab, at its state-of-the-art biologics facility in Guangzhou, China.

A warm welcome from BeiGene CEO John V. Oyler on the Company's virtual congress site.

Discover how BeiGene has developed a multi-national platform for global drug development. With the winning combination of world class drugs and a world class team, our innovative approach is unique, and our company is going from strength to strength.